The German Breast Group conducts breast cancer research based on its own study concepts. We intend to undertake further scientific research projects in the interests of gaining a better understanding of the disease.
In order to find out more about the causes and the progression of breast cancer, the German Breast Group has set up a sub-board for translational research. Its members work at the interface between clinical and experimental science with the aim of developing therapies tailored to the individual needs of patients.
The goal of EURECA (Enabling information re-Use by linking clinical REsearch and Care) is to enable seamless, secure, scalable and consistent linkage of healthcare information residing in electronic health record (EHR) systems with information in clinical research information systems, such as clinical trials.
RESPONSIFY intends to prove the hypothesis that a predictive biomarker approach will be able to distinguish responders from non-responders and will therefore spare patients from unnecessary toxicities. This will help to significantly reduce costs in the European healthcare system and improve prognosis and quality of life for women diagnosed with breast cancer. Using new genome-wide based techniques, we will select and validate candidate biomarkers which have the potential to predict response to therapy and affect clinical outcome.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440